Korean Cosmetics Franchise vs Private Label vs OEM vs ODM: Indie Brand Decision Guide (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

A first-time founder who walks into the Korean beauty supply chain in 2026 hears four words used almost interchangeably: franchise, private label, OEM, ODM. They are not the same deal. They are four different commitments, with four different cost curves, four different IP positions, and four different exits if the brand stalls or accelerates.

We have reviewed roughly 80 indie brand engagements over the last 18 months at ALTA MEET, and the most expensive mistake we see is not picking the wrong factory. It is picking the wrong partnership model and discovering 14 months later that the model cannot scale with the brand. A founder who signed a franchise contract because it "sounded simpler" cannot reformulate. A founder who signed an OEM contract because she wanted "full ownership" is sitting on $80,000 of testing bills before her first PO ships. A founder who picked private label because it had the lowest MOQ is now being undercut by three other brands selling her exact formula under different names.

This guide compares all four models on the dimensions that actually move launch outcomes: formula ownership, MOQ, lead time, total first-launch cash, exclusivity, control over reformulation, and what each model lets you do in year three.

The four models, defined

Outside of the K-beauty supply chain these terms get used loosely. Inside it, they describe specific contracts with specific risks. Here is the working definition each one carries when a Korean factory or distributor uses it in a quote.

Private Label. A Korean manufacturer's existing formula, already developed, stability tested, and regulatory cleared, gets sold under your brand name. You select from a catalog, customize the secondary packaging and label, and ship. The formula is not exclusive to you. The manufacturer can and usually does sell the same formula to other brands under different names. Typical Korean private label MOQ runs 500 to 2,000 units. Time from PO to first shipment is 6 to 10 weeks, per published Korean private label timelines (knok global).

ODM (Original Design Manufacturer). You bring a brief that names the target consumer, the claims, the sensorial direction, the INCI restrictions, and the packaging concept, and the Korean factory's R&D lab develops the formula for you. You review and approve sample iterations. The formula can be exclusive to you for a defined window if you negotiate it, but the default assumption in Korean ODM contracts is that the manufacturer retains background IP and may reuse it. Typical ODM MOQ runs 1,000 to 3,000 units at mid-tier factories. Time from brief to first shipment is 12 to 18 weeks for a single SKU. ODM is the most common entry path for first-time founders sourcing in Korea.

OEM (Original Equipment Manufacturer). You arrive with the formula. Either you developed it yourself, you bought it from a freelance cosmetic chemist, or you brought one over from a prior factory. The Korean manufacturer's job is to produce it at scale with their quality systems and supply chain. You own the formula IP outright. Korean OEM MOQ typically starts at 3,000 to 5,000 units and rises with the complexity of the formula. Lead time from formula validation to first shipment runs 16 to 24 weeks because the formula has to be re-engineered for the factory's equipment and re-tested for stability under their conditions (Mayk OEM/ODM differences).

Franchise. A different category entirely. Here, an existing Korean brand grants you the right to operate under its name in a defined territory, sell its existing product line, and use its retail format. You are not building a brand. You are buying into a brand someone else built. You pay an initial franchise fee, ongoing royalties, and typically a monthly marketing contribution. You commit to a multi-year exclusivity, and the franchisor controls assortment, pricing bands, and visual identity. As a reference, Kskin Korean Express Facial discloses initial investment of roughly USD 150,000 to USD 600,000 depending on format and territory, with payback estimated around 24 months (SMERGERS Kskin profile).

Conflating these four is the easiest way to misprice a launch. A founder asking "should I go private label or franchise?" is comparing a product-sourcing model to a retail-operating model. The answer depends on whether she wants to build a brand or run someone else's storefront. For founders earlier in the decision (still comparing the three manufacturing models without the franchise overlay), our ODM vs OEM vs private label primer for indie founders covers the three-way version of this comparison.

Side-by-side comparison

These ranges are aggregated from published Korean factory guides, our own engagement review at ALTA MEET, and franchise disclosure references. Use them as orientation, not as a quote.

DimensionPrivate LabelODMOEMFranchiseWhat you bringBrand name, packagingBrief, target consumerA finished formulaCapital, retail locationWhat you getA relabeled stock formulaA new formula to your briefProduction of your formulaRight to operate under a Korean brandFormula exclusivityNone by defaultNegotiable, 1-2 yr typicalFullNone (you sell their products)Korean MOQ (per SKU)500-2,000 units1,000-3,000 units3,000-10,000 unitsInventory commitment, not MOQLead time (first ship)6-10 weeks12-18 weeks16-24 weeks4-8 months to open storeTypical first-launch cash (3-5 SKUs)$15k-$45k$35k-$120k$80k-$250k$150k-$600kWho owns the IPManufacturerMixed (negotiate)YouFranchisorReformulation controlNoneHigh once developedFullNoneResale of finished productYesYesYesWithin franchise rules onlyBest year-3 outcomeMove to ODM or OEMMove to OEMMulti-factoryAdd second locationWorst year-3 outcomeSame formula sold by 5 competitorsManufacturer reuses your brief in adjacent SKUSunk testing on a slow sellerBrand strategy changes outside your control

The first three rows are the load bearing ones. If you cannot answer "what do I bring, what do I get, who owns the IP" with confidence for a given quote, you have not yet understood the deal you are about to sign.

Private Label: the fastest, cheapest, lowest-risk entry

Private label exists because Korean ODMs achieve massive economies of scale by producing billions of units annually, which drives down unit costs significantly and lets indie brands sell high-quality serums and creams at retail price points the rest of the world cannot match (Georgetown Journal of International Affairs on K-Beauty Trinity). When a Korean factory has already stability tested a centella mucin essence at 1,500 batches, the marginal cost of running 1,000 more units for a new brand is small. That is the economic engine private label rides on.

What you actually buy in a private label deal: a stock SKU from the factory's catalog, customization of secondary packaging (the bottle shape, the carton, the label), and a finished good with the factory's CoA and stability data already in hand. In Korea, 2026 private label catalogs commonly include centella, mucin, rice, propolis, niacinamide, retinal, and ceramide variants in toner, essence, ampoule, cream, and sheet mask formats. A founder can launch a 3-SKU starter line for a documented total of roughly $15,000 to $45,000 including packaging, label design, regulatory filing, and first inventory (knok private label guide). For a deeper look at how Korean factories actually quote a 1,000-unit private label run, our low-MOQ Korean skincare manufacturing playbook walks the numbers line by line.

What you do not get: exclusivity. The same formula in your essence bottle is also in three other indie brand bottles, often with different price points and different claim sets. The factory does not tell you who else is on the formula. Some Korean private label houses publish their catalog publicly, which means a competitor or a curious retailer can search for "centella mucin essence Korea private label" and find your formula match in 10 minutes.

The right founder for private label is a brand whose competitive moat is not the formula. It is the audience, the brand story, the photography, the channel, or the price position. If your brand differentiator is "I am building a community around perimenopause skincare for Latinx women," the underlying formula being shared with three other brands is not the brand's problem. If your brand differentiator is "this peptide stack is unique," private label is the wrong door.

Private label also works as a learning step. We have seen founders launch 3 SKUs on private label, run them for 12 to 18 months, capture purchase data, identify the SKU that consistently outperforms, and then commission an ODM reformulation of that one hero SKU with a meaningful upgrade. That is a defensible path. Starting private label is not a commitment to stay private label.

ODM: the default Korean entry for branded indie skincare

ODM is the partnership model that built K-beauty's indie boom. You bring a brief that includes target consumer, claims framework, sensorial profile (texture, slip, after-feel), INCI must-haves and must-avoids, target retail price, and packaging concept. The factory's R&D lab develops three to five prototypes, you iterate, you approve a final formula, you run patch and stability testing, and you produce.

The cost structure differs from private label because R&D time is real. A typical Korean ODM development engagement for a single SKU at a mid-tier factory runs $3,000 to $8,000 in formulation fees, $1,200 to $2,500 in stability and patch testing per SKU, and $1.50 to $7.00 per unit at 1,000 to 3,000 MOQ depending on actives and packaging. For a 3-SKU launch a founder should plan for total first-launch cash of $35,000 to $120,000 (ALTAMEET Korean skincare manufacturing cost breakdown).

The IP situation in Korean ODM contracts is where most first-time founders lose money. The default Korean ODM contract gives the manufacturer ownership of the developed formula and a license to you to sell it. That means the manufacturer can take your brief, say "centella + 5% niacinamide + 3% propolis essence at pH 5.3 with a slip-heavy after-feel," and after your exclusivity window expires sell substantially the same formula to another brand. Sometimes that exclusivity window is 12 months. Sometimes 24. Sometimes there is no exclusivity at all unless you ask in writing.

What founders should negotiate at the brief stage, before any deposit:

• Formula ownership and an exclusivity window of at least 18 months on the specific formulation

• A non-circumvention clause covering the active stack you specified

• Written ownership of the visual brief, the packaging design, and the brand pin board

• A reformulation clause that lets you take the formula to a second factory if production quality drops

• Right of first refusal on the next 12 months of factory innovation in your category

We have walked founders through these conversations dozens of times. None of them are unreasonable. Most Korean ODMs will agree to at least three of the five if asked, especially at the deposit stage when the factory is bidding for the project. None will offer them unprompted.

I'm Liz, I run ALTA MEET from Manhattan, NYC. The hardest conversation in any ODM contract is the one about what happens to your formula in month 13. If you want a quick gut-check on the contract you are about to sign, grab 15 minutes free with Liz and we will walk through the IP clauses together.

OEM: when the formula is the brand

OEM is the right model when the formula itself is the differentiation. A founder who has spent two years working with a freelance cosmetic chemist on a specific peptide stack does not want a Korean ODM lab "improving" it. She wants a Korean factory producing it under her quality system, with her IP, on her timeline.

The economics are different from ODM in three ways. First, the factory does not earn a formulation fee. That is a small saving, usually $3,000 to $8,000. Second, the factory has to run a process transfer because your formula was developed on someone else's equipment. Process transfer typically takes 8 to 14 weeks and runs $5,000 to $20,000 depending on the formula's complexity and how complete your existing process documentation is. Third, the factory wants higher MOQ on OEM contracts because they are taking on schedule risk for a formula they did not develop. Korean OEM contracts at mid-tier factories typically start at 3,000 to 5,000 units per SKU, with premium factories often requiring 10,000-plus (OEMKorea pricing guide).

The full first-launch cash for a 3-SKU OEM line in Korea typically lands between $80,000 and $250,000 once you account for process transfer, expanded stability testing because your existing data was generated elsewhere, expanded patch testing, regulatory filing (US MoCRA, KFDA notification if you intend to sell in Korea, EU CPNP if you intend to sell into Europe), and first inventory at the higher MOQ.

The upside is full IP ownership. You can move the formula to a second factory if your primary OEM partner has a quality issue or a capacity issue. You can license the formula. You can sell the formula to an acquirer as part of your brand exit. That portability is what justifies the upfront cost. If your brand's exit thesis depends on the formula being a defensible asset, you do not want it sitting on a manufacturer's IP shelf.

Franchise: a retail business, not a brand business

The franchise model in K-beauty is fundamentally a different decision than the prior three. You are not creating a product. You are buying into someone else's product line and operating it under their brand name in a territory they grant you.

In the United States, any franchise sale is governed by the FTC Franchise Rule (16 CFR Part 436). The franchisor must give you a Franchise Disclosure Document at least 14 calendar days before you sign anything or pay any money (FTC Franchise Rule guidance). The FDD has 23 specific items: franchisor history, fees, franchisee obligations, territory definitions, training, financial performance, litigation history, audited financials, and the full franchise agreement. Read all 23 items, and read them twice. Item 19 (financial performance representations) and Item 20 (outlet and franchisee information including closures) are where the lived reality of the franchise shows up.

Initial investment in Korean cosmetics retail franchises in 2026 typically falls in the range of $150,000 to $600,000 for facility build-out and opening inventory, with payback timelines averaging around 24 months at functioning locations of established franchisors like Kskin (Kskin franchise profile, SMERGERS). Ongoing royalties and territorial marketing fees vary by franchisor and contract; the FDD will spell them out in Item 5 and Item 6.

What the franchise model gives you: instant brand recognition in your territory, a proven retail format, a tested assortment, and operational training. What it takes away: control over reformulation, control over price positioning beyond a band, control over assortment, control over visual identity, and the right to sell into channels the franchisor has not approved. If the franchisor pivots strategy in year four, your business pivots with it whether you agree or not.

The right founder for a Korean beauty franchise is not the same person who is right for private label, ODM, or OEM. The franchise founder is operating a retail business, optimizing for foot traffic, service throughput, and recurring local customer relationships. The product-brand founder is operating a brand business, optimizing for awareness, social commerce, retention, and gross margin. These are different jobs.

What the first-launch cash actually looks like

Looking at our engagement review for 2024-2026, the documented first-launch totals broke down roughly as follows for a US-headquartered indie founder launching a 3-SKU line in Korea. Numbers are total cash through first shipment, including formulation, testing, regulatory filing, packaging and label design, and first inventory. They do not include marketing spend, channel investment, or the founder's own time.

The Private Label path averaged around $28,000 for a 3-SKU launch at 1,000 units per SKU, ranging from $15,000 (stock packaging, minimum customization, basic label) to $45,000 (custom secondary packaging, premium label finish, larger first inventory).

The ODM path averaged around $72,000 for a 3-SKU launch at 1,500 units per SKU, ranging from $35,000 (mid-tier factory, single-active formulas, stock primary packaging) to $120,000 (premium-tier factory, multi-active formulas, custom primary packaging, MoCRA filing).

The OEM path averaged around $145,000 for a 3-SKU launch at 5,000 units per SKU, ranging from $80,000 (process transfer of established formulas to a mid-tier factory) to $250,000 (full process transfer plus expanded stability and patch testing plus EU CPNP filing).

The Franchise path is in a different scale entirely, with the Kskin reference range of $150,000 to $600,000 covering opening inventory, store build-out, training, initial franchise fee, and pre-opening marketing.

Three observations a founder should sit with before signing anything.

First, the dollar range inside one model is often wider than the gap between models. A premium ODM launch at $120,000 costs more than a mid-tier OEM launch at $80,000. The right question is not "which model is cheapest" but "which model gives me the right IP position for the cash I am putting in."

Second, the cash through first shipment is the smaller number. The cash through SKU 4, 5, and 6 is the larger one. Private label founders re-buy inventory in the same model. ODM founders develop additional SKUs at $3,000 to $8,000 per formulation plus stability and patch testing. OEM founders have to repeat the process transfer story for every new factory partner. Franchise founders may face per-SKU royalty escalators that are not visible in Year 1.

Third, the testing and regulatory layer scales with where you intend to sell, not with your model. A founder who is launching DTC in the US can defer MoCRA registration to within 60 days of marketing (current MOCRA timeline) and skip EU CPNP entirely. A founder who knows in Year 1 she wants to enter EU mass retail in Year 2 should spend the extra $4,000 to $8,000 on CPNP-ready dossiers during initial development. The model does not change the regulatory load; the market does.

Decision framework: which model fits which founder

The right model is the one that matches the founder's brand thesis, capital position, and three-year plan. The four questions below tend to surface the answer in one conversation.

1. What is the brand's competitive moat?

If the moat is the formula itself, a proprietary peptide stack, an unusual delivery system, a clinical study that took years to design, go OEM. The formula needs to be a portable IP asset.

If the moat is the audience and the brand story, a specific community, a specific aesthetic, a specific founder narrative, go ODM. You want a good formula but you do not need an unrepeatable one. Negotiate an 18 to 24 month exclusivity window.

If the moat is speed, price position, or channel (fastest-to-shelf, lowest landed cost, exclusive in a niche retail channel), go private label. Get to market in 8 weeks, prove the channel, then upgrade to ODM on the proven SKUs.

If the moat is a retail location and a service-driven customer relationship in a defined territory, go franchise. The product is not the moat; the foot traffic is.

2. What is the realistic first-12-months cash position?

Under $50,000 available for product (not including marketing): private label.

$50,000 to $150,000: ODM, mid-tier factory, 3 SKUs at 1,500 units each.

$150,000 to $300,000: OEM if formula IP justifies the cost, or premium ODM with custom packaging and expanded testing if not.

$300,000-plus and a tolerance for fixed-location operating risk: franchise becomes possible.

3. What does year three look like?

If year three is "I want to be acquired by a strategic for the brand and the formula portfolio," go ODM or OEM and document IP cleanly from day one. Acquirers diligence formula ownership and will haircut the valuation if the formulas sit on the manufacturer's IP shelf.

If year three is "I want a profitable indie brand running on the original assortment with steady reorders," private label is durable. We have seen private label brands run 5 to 7 years profitably on the same formula library.

If year three is "I want 3 retail locations and a local services business," franchise is the only model that makes that operationally tractable in 36 months.

4. What is the brand willing to give up?

OEM gives up speed and cash. ODM gives up some exclusivity flexibility. Private label gives up formula uniqueness. Franchise gives up brand control. Pick the trade-off you can live with.

Common mistakes we keep seeing

Across roughly 80 founder engagements in the last 18 months, the same five mistakes recur often enough that we put them in every founder onboarding email.

Mistake one: signing an ODM contract without an exclusivity clause. Default Korean ODM contracts grant no exclusivity. If the contract is silent on exclusivity, assume the formula will be resold. Ask for at minimum 12 months and ideally 24 months written exclusivity on the specific formula.

Mistake two: confusing "private label" and "white label" pricing assumptions with OEM-grade IP ownership. A founder who pays private label pricing should expect private label IP terms (none). A founder who wants formula ownership should expect to pay OEM-grade development and process transfer costs. The two cannot be combined.

Mistake three: underestimating Korean MOQ negotiation flexibility. Korean Tier 2 and Tier 3 manufacturers will negotiate MOQ in exchange for multi-SKU commitments, deposit increases, or shorter payment terms. Founders who accept the published MOQ as fixed leave 20 to 40 percent of cash flexibility on the table. (Tier breakdown reference)

Mistake four: signing a distribution or franchise agreement without modeling the 80 percent minimum purchase clause. Korean distribution and franchise contracts commonly include a minimum purchase threshold. The supplier can revoke exclusivity if the distributor fails to achieve, typically, 80 percent of an agreed annual target (Atlas Legal exclusive distributor advisory). Model the Year 1 sell-through pessimistically before agreeing to a number you cannot hit.

Mistake five: skipping the 14-day FDD review window on franchise opportunities. US franchise law requires the franchisor to give you 14 calendar days with the FDD before you sign anything or pay anything. Use the 14 days. Hire a franchise attorney (typical fee $2,000 to $5,000 for a single-franchise review) to read Items 5, 6, 17, 19, 20, and 22. The fee is small relative to a $150,000-plus commitment.

How to test the partnership before you commit

Before any model is signed, three steps reduce downside risk meaningfully.

Step one, request a manufacturing reference list and call two existing brands. Ask about communication cadence, sample iteration count, lead time accuracy, and post-production support. A factory that will not give references is a factory whose references have stories.

Step two, request the factory's most recent ISO 22716 surveillance audit report and the executive summary of their last regulatory inspection (KFDA for Korean factories). Look for non-conformances, root causes, and corrective action closure dates. The pattern of non-conformances tells you more about quality culture than the marketing deck.

Step three, run a paid sample order in your packaging. For private label and ODM this is a 100 to 300 unit pilot. For OEM it is a 500 to 1,000 unit process verification batch. For franchise it is a multi-day site visit to two existing franchisees in the same region. The pilot or visit cost is small relative to the cost of a wrong-model commitment.

Frequently asked questions

Can I start private label and move to ODM later? Yes, and we recommend it for founders whose audience hypothesis is still forming. Run 12 to 18 months on private label to capture purchase data and identify the SKU with consistent repurchase rate. Then commission an ODM reformulation of that hero SKU with a meaningful upgrade. The transition is straightforward and the data you collect on private label de-risks the ODM brief.

Can I own the formula on a private label deal? No. Private label means the manufacturer's stock formula sold under your label. If you want formula ownership, you need ODM (with strong contractual exclusivity) or OEM.

What is the difference between white label and private label in Korea? The two terms are used loosely in the market. As Korean factories use them in 2026, "white label" tends to mean a fully stock formula with stock packaging and minimal customization (often just a label). "Private label" tends to mean stock formula with customized secondary packaging. Both have no formula exclusivity. The distinction matters less than the IP terms in the actual contract.

How long should ODM formula exclusivity last? We negotiate 18 to 24 months as the default ask. Below 12 months the exclusivity is too short to capture a season-over-season reorder cycle. Above 36 months is unusual at mid-tier factories without a meaningful upfront retainer.

Is franchise ever the right model for a product-brand founder? Rarely. Founders who want to build a product brand are signing up for a different game than franchise operators are signing up for. The two roles compete for the same hours in the day and reward different skills. The exception is a product-brand founder who wants a flagship retail location for marketing reasons, in which case a single owned store, not a franchise, is usually the better structure.

How much does ALTA MEET cost? We work on retainer ($4,000 to $9,000 per month depending on scope) or project basis ($15,000 to $50,000 for a defined launch through first shipment). The first 15-minute conversation is free.

Working with ALTA MEET

ALTA MEET is a small NYC × Seoul consultancy. We help US indie founders pick the right Korean partnership model, negotiate the contracts that protect the brand's IP and exit path, and run the Seoul-side oversight that keeps quality and timeline on track. We have walked roughly 80 founders through these decisions in the last 18 months. Most of them were comparing exactly the four models above when we first spoke.

If you are sitting on a quote and want a second pair of eyes, book a free 15-min gut-check with Liz. The conversation is private, the advice is specific to your situation, and we will tell you honestly when the right answer is "do not sign this."

Reviewed for accuracy by ALTA MEET's formulation consulting team. Last updated June 2026.

Key takeaways

• Private label, ODM, OEM, and franchise are four different commitments with four different IP positions. Conflating them is the most common indie launch mistake.

• Private label: 6-10 week lead time, $15k-$45k for a 3-SKU launch, no formula exclusivity. Best when the moat is audience or channel, not formula.

• ODM: 12-18 week lead time, $35k-$120k for a 3-SKU launch, exclusivity is negotiable. The default entry for branded indie skincare. Negotiate 18-24 months written exclusivity at the brief stage.

• OEM: 16-24 week lead time, $80k-$250k for a 3-SKU launch, full IP ownership. Right when the formula itself is the brand's competitive moat and acquirer-ready IP matters.

• Franchise: $150k-$600k initial investment, 24-month payback at established operators, operates under the franchisor's brand. A retail business decision, not a product brand decision. FTC requires a 14-day FDD review window.

• Five recurring mistakes: missing ODM exclusivity clauses, mixing private label pricing with OEM IP expectations, accepting published MOQ as fixed, ignoring 80% minimum purchase clauses, skipping the 14-day FDD review.